Brief: Coya Therapeutics Reports Additional Proof-Of-Concept Clinical Biomarker Data In Patients With Alzheimer’S Disease
17/07/2023 12:06
July 17 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS REPORTS ADDITIONAL PROOF-OF-CONCEPT
CLINICAL
BIOMARKER DATA IN PATIENTS WITH ALZHEIMER’S DISEASE
* COYA THERAPEUTICS INC - TREATMENT WITH LD IL-2
ADMINISTERED
SUBCUTANEOUSLY APPEARED TO BE SAFE AND WELL TOLERATED IN
PATIENTS WITH AD
* COYA THERAPEUTICS - ONGOING PHASE 2, DOUBLE BLIND, PLACEBO
CONTROLLED TRIAL IS ALMOST FULLY ENROLLED, SHOULD REPORT TOP
LINE RESULTS IN JULY, 2024
* COYA THERAPEUTICS INC - OVERALL, ADMINISTRATION OF LD-IL-2
APPEARED TO BE SAFE AND WELL TOLERATED
* COYA THERAPEUTICS INC - MOST COMMON ADVERSE EVENTS OF
LD-IL-2
WERE MILD INJECTION-SITE REACTIONS AND MILD LEUKOPENIA
* COYA THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS WERE
REPORTED,
AND NO PATIENT DISCONTINUED STUDY
Source text for Eikon: ID:nBw4xsnnVa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)